Impact Story
3m Read
September 10, 2024
ANTIMICROBIAL STEWARDSHIP
Article
5m Read
November 14, 2025
ANTIMICROBIAL STEWARDSHIP
Main Menu
-
Solutions
Back
Cepheid’s Solutions
-
Global Access
-
Testing Everywhere
Back
Testing Everywhere
-
Antibiotic Stewardship
-
Customized Testing for Your Institution
-
Knowing MORE Matters
-
-
Insights
Back
Cepheid’s Insights
-
Webinars
Back
Webinars
-
Cepheid RADAR
Back
Cepheid RADAR
-
Support
Back
Support Center
-
Documents & Technical Resources
-
Troubleshooting and How-tos
-
MyCepheid and Order Support
-
Contact Us
Back
Contact Us
-
-
About Us
Back
About Cepheid
-
Mission and History
Back
Mission and History
-
Our Leadership
Back
Our Leadership
-
Events
Back
Events
-
Distributors
Back
Distributors
-
Business Development Opportunities
-
Innovate with Cepheid
-
Meet the Cepheid Bike
-
News
Back
News
-
Careers
Back
Careers
-
The Need
- Hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections are a major cause of morbidity and mortality worldwide1
- People with methicillin-resistant Staphylococcus aureus (MRSA) infections are 64 % more likely to die than people with drug-sensitive infections2
- Active surveillance of inpatients for MRSA is a strategy for preventing health care-acquired infections (HAIs) by MRSA1
1 Yarbrough M, et al. Multicenter evaluation of the Xpert MRSA NxG assay for detection of methicillin-resistant Staphylococcus aureus in Nasal Swabs. J Clin Microbiol. 2017 Dec;56(1).
2 World Health Organization. (n.d.). Antimicrobial resistance. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
2 World Health Organization. (n.d.). Antimicrobial resistance. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
The Solution
- Xpert® MRSA NxG is a qualitative in-vitro diagnostic test intended for the detection of methicillin-resistant S. aureus (MRSA) DNA directly from nasal swabs in patients at risk for nasal colonization*
- Quickly identify MRSA-colonized patients who may require contact precautions to aid with transmission risks and outbreak management
* Xpert MRSA NxG was compared to a Reference Culture Method. See Package Insert for additional details.
The Impact
- Rapid implementation of infection control measures and patient bed management1
- Strong clinical performance compared to other commercial tests1
- Minutes of hands-on time with results in 70 minutes on a random-access platform1
1 Yarbrough M, et al. Multicenter evaluation of the Xpert MRSA NxG assay for detection of methicillin-resistant Staphylococcus aureus in Nasal Swabs. J Clin Microbiol. 2017 Dec;56(1).